Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study
- PMID: 20503453
- PMCID: PMC2877183
- DOI: 10.3748/wjg.v16.i20.2531
Nonalcoholic fatty liver disease and HFE gene mutations: a Polish study
Abstract
Aim: To describe a Polish population with nonalcoholic fatty liver disease (NAFLD) with regard to HFE gene mutations, as well as analyzing demographic and clinical data.
Methods: Sixty-two consecutive patients with biopsy-proven NAFLD were included in the study. Demographic, clinical, and laboratory data were summarized in a database. C282Y and H63D mutations of the HFE gene were analyzed using polymerase chain reaction-restriction fragment lenght polymorphism.
Results: The analyzed cohort consisted of 62 homogeneic Caucasian participants, 66.1% men and 33.9% women, with a median age of 48 years. The median body mass index was 29.05 kg/m(2). Hypercholesterolemia was observed in 74.2% of patients and hypertriglyceridemia in 32.2%; 16.1% had type 2 diabetes mellitus (DMt2). On liver biopsy, 22.6% of NAFLD patients were found to have severe fibrosis. There were no differences between frequencies of HFE gene mutations in subgroups of NAFLD patients with less and more severe liver fibrosis. Obesity, older age, female gender and DMt2 were associated with more advanced fibrosis in this Polish cohort, as well as higher glucose level, serum iron and transaminase aspartate aminotransferase/alanine aminotransferase ratio.
Conclusion: HFE mutations conferred no additional hepatic fibrosis risk in NAFLD, but higher serum iron was a risk factor for severe liver damage in NAFLD, regardless of HFE mutations.
Similar articles
-
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology. 2010 Mar;138(3):905-12. doi: 10.1053/j.gastro.2009.11.013. Epub 2009 Nov 18. Gastroenterology. 2010. PMID: 19931264
-
HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity.Hepatology. 2002 Jul;36(1):142-9. doi: 10.1053/jhep.2002.33892. Hepatology. 2002. PMID: 12085358
-
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.Hepatology. 2004 Jan;39(1):179-87. doi: 10.1002/hep.20023. Hepatology. 2004. PMID: 14752836
-
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.Hepatology. 2012 Nov;56(5):1730-40. doi: 10.1002/hep.25856. Epub 2012 Sep 20. Hepatology. 2012. PMID: 22611049 Free PMC article.
-
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis.Hepatology. 2007 Sep;46(3):723-9. doi: 10.1002/hep.21742. Hepatology. 2007. PMID: 17680648
Cited by
-
Molecular Pathogenesis of NASH.Int J Mol Sci. 2016 Sep 20;17(9):1575. doi: 10.3390/ijms17091575. Int J Mol Sci. 2016. PMID: 27657051 Free PMC article. Review.
-
Genetic background in nonalcoholic fatty liver disease: A comprehensive review.World J Gastroenterol. 2015 Oct 21;21(39):11088-111. doi: 10.3748/wjg.v21.i39.11088. World J Gastroenterol. 2015. PMID: 26494964 Free PMC article. Review.
-
Genetic variants in HFE are associated with non-alcoholic fatty liver disease in lean individuals.JHEP Rep. 2023 Mar 27;5(7):100744. doi: 10.1016/j.jhepr.2023.100744. eCollection 2023 Jul. JHEP Rep. 2023. PMID: 37235137 Free PMC article.
-
Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015. BMJ Open Gastroenterol. 2015. PMID: 26462272 Free PMC article.
-
Iron overload disorders.Hepatol Commun. 2022 Aug;6(8):1842-1854. doi: 10.1002/hep4.2012. Epub 2022 Jun 14. Hepatol Commun. 2022. PMID: 35699322 Free PMC article. Review.
References
-
- de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104–S112. - PubMed
-
- Pietrangelo A. Iron in NASH, chronic liver diseases and HCC: how much iron is too much? J Hepatol. 2009;50:249–251. - PubMed
-
- Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, Massarenti P, Piga A, Marchesini G, Rizzetto M. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–187. - PubMed
-
- Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care. 2005;28:2061–2063. - PubMed
-
- Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, Mariani R, Mancia G. Increased serum ferritin is common in men with essential hypertension. J Hypertens. 2002;20:1513–1518. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources